An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis

Carin H. Gribetz, Robin Blum, Christopher Brady, Steven Cohen, Mark Lebwohl

Research output: Contribution to journalArticle

41 Scopus citations

Abstract

Background: The efficacy and safety of one and two courses of alefacept have been demonstrated in phase 2 and 3 clinical trials, with a course of alefacept defined as 12 weeks of once-weekly treatment followed by 12 weeks of observation. Methods: This randomized, single-center study compared the safety and efficacy of a standard 12-week versus extended 16-week alefacept dosing period in 20 patients with chronic plaque psoriasis. Results: Both dose groups showed marked improvement in mean Psoriasis Area and Severity Index (PASI) score from baseline through week 24 (between-group difference: not significant). In each group, 60% of patients achieved PASI 50 (≥50% reduction from baseline PASI score) at any time between weeks 12 and 24. For patients who received 16 weeks of alefacept, the mean percentage change from week-12 PASI score was higher and continued to increase through week 24 compared with that for patients who received 12 weeks of alefacept (P <. 05). Adverse events were similar between the two groups and comparable with those observed in phase 2 and 3 clinical studies of alefacept. Conclusions: This was an open-label, single-center study of 20 patients. Further study is warranted to assess the effect of alefacept when administered for more than 12 weeks. Extended dosing with alefacept appeared to have a similar safety profile to 12-week dosing and may offer further benefit to some patients for disease improvement.

Original languageEnglish (US)
Pages (from-to)73-75
Number of pages3
JournalJournal of the American Academy of Dermatology
Volume53
Issue number1
DOIs
StatePublished - Jul 1 2005
Externally publishedYes

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis'. Together they form a unique fingerprint.

  • Cite this